Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |
PMID | |
Authors | Matthew Alexander Lunning, Julie Vose, Nathan Hale Fowler, Loretta J. Nastoupil, Marshall T. Schreeder, Tanya Siddiqi, Christopher Flowers, Jonathon Brett Cohen, Susan Blumel, Myra Miguel, Warner H Tse, Emily K. Pauli, Kathy Cutter, Peter Sportelli, Hari |
Title | Ublituximab plus TGR-1202 activity and safety profile in relapsed/refractory B-cell NHL and high-risk CLL. |
Journal | J Clin Oncol |
Vol | |
Issue | |
Date | |
URL | http://meetinglibrary.asco.org/content/152562-156 |
Abstract Text | J Clin Oncol 33, 2015 (suppl; abstr 8548) |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
Unknown unknown | follicular lymphoma | not applicable | Ublituximab + Umbralisib | Phase I | Actionable | In a Phase I trial, high-dose Ukoniq (umbralisib) in combination with Ublituximab resulted in complete response in 17% (1/6) and partial response in 33% (2/6) of patients with follicular lymphoma (J Clin Oncol 33, 2015 (suppl; abstr 8548)). | detail... |
Unknown unknown | chronic lymphocytic leukemia | not applicable | Ublituximab + Umbralisib | Phase I | Actionable | In a Phase I trial, Ukoniq (umbralisib) and Ublituximab combination treatment resulted in a median progression-free survival of 8 months in all 10 chronic lymphocytic leukemia patients, with partial response in 100% (3/3) of patients in the high-dose TGR-1201 group and 57% (4/7) in the low-dose group (J Clin Oncol 33, 2015 (suppl; abstr 8548)). | detail... |
Unknown unknown | diffuse large B-cell lymphoma | not applicable | Ublituximab + Umbralisib | Phase I | Actionable | In a Phase I trial, high-dose Ukoniq (umbralisib) in combination with Ublituximab resulted in complete response in 50% (2/4) and partial response in 25% (1/4) of patients with diffuse large B-cell lymphoma (J Clin Oncol 33, 2015 (suppl; abstr 8548)). | detail... |